Pre-clinical studies showed potent, selective lysis of ROR2-expressing cell lines and durable tumor regression in xenograft models, while non-human primates tolerated single doses up to 10 mg/kg with good systemic stability [146]. The gene discussed is ROR2; the disease is neoplasm.